HIV/AIDS Clinical Trials in Los Angeles

Showing 321-340 of 648 trials

A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services

NCT01781806

The purpose of this study is to evaluate the safety, acceptability and feasibility of delivery of Pre-Exposure Prophylaxis (PrEP) or Post-Exposure Prophylaxis) PEP as part of combination HIV prevention services for high-risk MSM and transgender women.

HIV Prevention

University of California, Los Angeles328 participantsStarted May 2013

Los Angeles, California, United States • Los Angeles, California, United States

COMPLETEDPhase 3< 1 mile

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

NCT01263015

The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of Bristol-Myers Squibb and Gilead Sciences LLC) over 48 weeks; non-inferiority will also be tested at Week 96. This study will be conducted in HIV-1 infected ART-naïve adult subjects. Long term antiviral activity, tolerability, safety, and development of viral resistance will be evaluated.

Infection, Human Immunodeficiency Virus I

ViiV Healthcare844 participantsStarted Feb 2011

Hobson City, Alabama, United States • Little Rock, Arkansas, United States • Bakersfield, California, United States +142 more locations

A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

HIV/AIDS Trials in Other Cities

Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng

Testosterone and Physical Function in HIV+ Men

Medications for Chronic HIV: Education and Collaboration

Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Enhancing Housing First Programs With a Social Network Substance Use Intervention

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?

Other Conditions in Los Angeles